A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-21

Study Completion Date

2021-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial is to investigate pharmacokinetics, including dose proportionality, following single intravenous and subcutaneous doses of spesolimab in healthy Chinese subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

NCT03123094

Healthy

COMPLETED PHASE1

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

NCT02852824

Healthy

COMPLETED PHASE1

Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers

NCT02331277

Healthy

COMPLETED PHASE1

Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants

NCT06662123

Healthy Volunteers

COMPLETED PHASE1

This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated

NCT03206632

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spesolimap (BI 655130) - 450 milligram (mg) - intravenous (IV)

A single dose of 450 mg Spesolimap was administered as solution for infusion intravenously over 90 minutes (mins) after an overnight fast.

Group Type EXPERIMENTAL

Spesolimap

Intervention Type DRUG

Spesolimap

Spesolimap - 900 mg - IV

A single dose of 900 mg Spesolimap was administered as solution for infusion intravenously over 90 mins after an overnight fast.

Group Type EXPERIMENTAL

Spesolimap

Intervention Type DRUG

Spesolimap

Spesolimap - 1200 mg - IV

A single dose of 1200 mg Spesolimap was administered as solution for infusion intravenously over 90 mins after an overnight fast.

Group Type EXPERIMENTAL

Spesolimap

Intervention Type DRUG

Spesolimap

Spesolimap - 300 mg - subcutaneous (SC)

A single dose of 300 mg Spesolimap was administered as solution for injection subcutaneously in the abdominal region within 60 seconds (s) after an overnight fast.

Group Type EXPERIMENTAL

Spesolimap

Intervention Type DRUG

Spesolimap

Spesolimap - 600 mg - SC

A single dose of 600 mg Spesolimap was administered as solution for injection subcutaneously in the abdominal region within 60 s after an overnight fast.

Group Type EXPERIMENTAL

Spesolimap

Intervention Type DRUG

Spesolimap

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spesolimap

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BI 655130

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or female subjects (at least three subjects for each gender within each dose group) according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR), respiratory rate (RR), body temperature), 12-lead ECG, and clinical laboratory tests.
* Chinese ethnicity, according to the following criteria: Ethnic Chinese, born in China and have 4 ethnic grandparents who were all born in China
* Age of 18 to 45 years (inclusive)
* Body weight ≥50 kg for male and ≥45 kg for female with body mass index (BMI) range ≥19 and \< 26 kg/m2 at visit 1
* Signed and dated written informed consent prior to admission to the trial, in accordance with GCP and local legislation
* Female subjects who meet any of the following criteria from at least 30 days before the first administration of trial medication until 16 weeks after trial completion \[c03320877-06\]:

* Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the subject information
* A vasectomised sexual partner (vasectomy at least one year prior to enrolment)
* Surgically sterilised (including hysterectomy)
* Postmenopausal, defined as at least one year of spontaneous amenorrhoea (in questionable cases a blood sample with simultaneous levels of follicle-stimulating hormone (FSH) above 40 U/L and estradiol below 30 mg/L is confirmatory)

Exclusion Criteria

* Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to treatment or planned within 12 months after screening, e.g. hip replacement
* Any finding in the medical examination (including BP, PR, RR, Body temperature or 12-lead ECG) deviating from normal and assessed as clinically relevant by the investigator
* Repeated measurement of systolic BP outside the range of 90 to 140 mmHg, diastolic BP outside the range of 50 to 90 mmHg, or PR outside the range of 50 to 90 bpm
* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
* Any evidence of a concomitant disease assessed as clinically relevant by the investigator
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
* History of relevant orthostatic hypotension, fainting spells, or blackouts

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes